MA09-hRPE

N/A

Report date: 2023/01/12 16:08:11

Base Information

Drug NameMA09-hRPE

Drug Alias NamehRPE cell therapyACT hESC-RPEHuman embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells-AstellasRPE cell therapy-AstellashESC-derived RPE +[7]

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Retinal pigment epithelial cell therapyCell and gene therapy > Cell therapy > Source of cells > Embryonic stem cell-derived

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsGeographic AtrophyMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomSouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAstellas Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesAstellas Institute For Regenerative Medicine

Inactive CompaniesCHA Biotech Co Ltd

Active IndicationsMacular Degeneration

Inactive IndicationsGeographic Atrophy

Other Information

ATC CodeN/A